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Abstract
Background: The key role of apolipoprotein C-1 (ApoC-1) is reported in breast, pancreas and lung cancer. However, no
information is available on potential difference of ApoC-1 between OSCC patients and healthy individuals. This work
aimed to examine the serum ApoC-1 level as well as lipid proﬁle values between OSCC patients and healthy control
groups.
Material and methods: In this study, 44 blood samples from 22 OSCC patients and 22 healthy individuals were collected
to determine the values of lipid proﬁle and ApoC-1 concentration using colorimetric method and Enzyme-Linked
Immunosorbent Assay (ELISA), respectively.
Results: A signiﬁcant decrease in serum lipid proﬁle and ApoC-1 concentration was observed between OSCC and
healthy control groups (P ¼ 0.001).
Conclusion: Our results conﬁrm the previous ﬁndings on the signiﬁcant differences of lipid proﬁle between OSCC and
controls, also show the lower serum level of ApoC-1 in OSCC as compared to the controls. Future studies would further
elaborate the association of ApoC-1 with OSCC.
Keywords: Oral squamous cell carcinoma, Serum lipid proﬁle, Serum ApoC1

1. Introduction

D

espite recent progress in therapeutic strategies, the outcome of Oral Squamous Cell
Carcinoma (OSCC) patients has not improved yet
[1]. OSCC accounts for more than 90% of all neoplasms in the oral cavity with a 5-year survival rate
less than 50% [2]. The diagnosis of OSCC occurs at
late stage and is more common in developing than
developed countries [3]. The major cell components
are lipids which have indispensable roles in
growing and dividing of normal and malignant tissues [4]. High rate of lipid peroxidation releases
peroxide radicals which attack essential components
of the cell membrane thus increase the demand on

lipids including total cholesterol, lipoproteins and
triglycerides for synthesis of new membrane [5].
Recent studies have shown the association of altered
lipid proﬁle with head and neck squamous cell
carcinoma, breast cancer, ovarian tumours and
colorectal cancer [6e9]. Apolipoproteins are key
proteins in regulation of lipoprotein metabolism,
their basic functions are lipid delivery, the activation
or inhibition of enzymes involved in metabolism of
lipoproteins and as ligands to recognize the lipoproteins' receptors [10]. Recently, published results
support abnormal expression of apolipoproteins in
tumours which is related to the prognosis of patients
[11]. Hence, the attention has focused on the association of apolipoprotein family in tumours' incidence and progression. ApoC-1 which belongs to
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apolipoprotein family contributes to the Chylomicron, VLDL and HDL-C metabolism [12] and its
involvement in progression of several diseases
including diabetes, polycystic ovary syndrome,
Alzheimer's disease and glomerulosclerosis has
been shown [13e15]. Although numerous studies
revealed that ApoC-1 is associated with the tumour
progression but the exact underlying mechanism
and signaling pathway of ApoC-1 in tumours is still
unclear [16e18]. The correlation of high tissue
expression and high preoperative serum concentration of ApoC-1 with poor prognosis of pancreatic
cancer patients has been reported by Li and colleagues [18]. Also, the diagnostic ability of overexpressed ApoC-1 has been reported to distinguish
triple negative breast cancer (TNBC) from nonTNBC (NTNBC) and is considered as a potential
prognostic biomarker for TNBC [19]. The upregulated mRNA and protein expression levels of ApoC1 in prostate cancer tissue is correlated with survival
of prostate cancer cells by inhibiting apoptosis, also
the increased serum level of ApoC-1 is associated
with the prognosis of prostate cancer patients [17].
The signiﬁcant decrease in serum levels of ApoC-1
has been reported in colorectal cancer, NSCLC
[11,20], papillary thyroid carcinoma [21] and child
nephroblastoma [22]. However, the serum level and
role of ApoC-1 in OSCC remain elusive. In this
experimental study, we sought to investigate and
compare the serum lipid proﬁle and ApoC-1 levels
of OSCC patients with healthy individuals.

2. Materials and methods

Table 1. Clinicopathological characteristics of OSCC patients and
healthy controls.
Characteristics

OSCC patients
(n ¼ 22)

Healthy controls
(n ¼ 22)

Age Mean (y)
Age (y)
60
>60
Sex
Female
Male
Grade
Grade I
Grade II
Grade III
Stage
I
II
III
IV
Tumour size
3.5 cm
>3.5 cm
Death
Yes
No
Vascular invasion
Yes
No
Perineural invasion
Yes
No
Tumour subsites
Oral cavity
Tongue
Mouth ﬂoor
Lip/Buccal mucosa
Maxilla
Mandible
Palate

63

62.4

7
15

10
12

11
11

8
14

13
7
2

e
e
e

3
5
6
6

e
e
e

10
10
1
21

0
22

6
8

e
e

7
7

e
e

1
5
1
9
2
2
2

e
e
e
e
e
e
e

2.1. Subjects
The serum samples of 22 patients diagnosed with
OSCC who had surgery from January 2019 to April
2021 were provided from a Pathology laboratory
(School of Dentistry, Cancer Institute Hospital) and
two hospitals (Bahman and Shariati hospitals) of
Tehran, Iran. The clinicopathological description of
study groups are shown in Table 1. All patients had
a histologically biopsy proven diagnosis for OSCC,
belonged to an age group of 38e84 years. Patients
who had other diseases or were under treatment
with medications that could affect their lipid proﬁle
(diabetes, liver failure or thyroid disorders) were
excluded. 22 healthy subjects of control group were
age- and gender-matched without any history of
major illness in the past. The tumours were graded
histologically to grade I (well-differentiated), grade
II (moderately differentiated) and grade III (poorly
differentiated) based on WHO criteria. Tumour
staging has been performed according to the

American Joint Committee on Cancer (AJCC).
Clinical information including age, gender, tumour
location were obtained from the information ﬁle of
patients. This study was performed at Clinical
Biochemistry department of Shahid Beheshti University of Medical Sciences (SBMU) under ethical
approval of SBMU: IR.SBMU.MSP.REC.1400.168.
2.2. Serum lipid proﬁle assessment
The lipid proﬁle tests measure serum total
cholesterol (TC), triglyceride (TG), HDL-C, LDL-C,
and VLDL. After a 12e14 h overnight fasting, 5 ml of
blood sample was collected under aseptic precautions in Serum Separator Tubes. To prepare the
serum, the collected blood samples were clotted for
1 h and then centrifuged for 10 min, 3000 rpm at
room temperature. The serum samples were stored
in the freezer 80  C until measurements. The serums were then analyzed for lipid proﬁle tests by
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the commercially available kits, Cholesterol (Pars
Azmoon, Iran), Triglyceride (biorexfars, Iran) and
HDL-C (PishtazTeb, Iran) using a biochemistry
autoanalyzer (BS-200 E, mindray, USA). The levels
of LDL-C and VLDL were calculated by the
following formula:
LDL-C ¼ (0.94  Total Cholesterol) e (0.94  HDLC) e (0.19  Triglyceride) [23].
VLDL ¼ TG/5 [24].
2.3. Serum ApoC-1 measurement
Concentrations of ApoC-1 in serum samples of
OSCC patients and healthy individuals were
determined by commercially ELISA kit (Invitrogen,
# EHAPOC1) following the manufacturer's protocol.
In brief, the wells in ELISA plate were coated with
100 ml of standards (concentrations from 3.2 to
50,000 pg/ml of ApoC-1) and samples (diluted with
sample diluents buffer in a proportion of 1/10,000)
and incubated 2.5 h at room temperature. Next,
plate contents were discarded and 300 ml of 1X wash
buffer was used to wash four times each well. Then,
100 ml of the biotinylated human anti-ApoC-1 conjugate was added to each well. The plate was incubated 1 h at room temperature with gentle shaking
and then the contents were removed and washed
four times with 1X wash buffer. After washing,
100 ml of the StreptavidineHRP solution was added
to each well and incubated 45 min at room temperature. Next, the solution was removed and each
well was washed four times with 1X wash buffer.
After washing, 100 ml of TMB solution was added to
each well and then incubated 30 min at room temperature in the dark with gentle shaking (The substrate began to turn blue). Next, the reaction was
stopped by adding 50 ml of the stop solution to each
well. The plate was immediately read at 450 nm.
The standard curve was generated using curveﬁtting software and Apo-C1 concentrations of unknown samples were determined from this standard
curve.
2.4. Statistical analysis
Data analysis was performed using GraphPad
Prism version 6 and data are expressed as
mean ± standard deviation (SD). Statistical analysis
was done using the ANOVA test and unpaired ttest. Correlation coefﬁcients were calculated using
the two-tailed Pearson's correlation analysis. In all
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the above tests, P-value < 0.05 was taken to be statistically signiﬁcant.

3. Results
3.1. Decreased serum levels of lipid proﬁle in
OSCC patients compared to healthy individuals
In this study, a total of 11 male and 11 female
patients with median age of 63 years were
included, of them 4.54% patients had lesion on oral
cavity, 9.09% on maxilla, 22.72% on tongue, 4.54%
on mouth ﬂoor, 40.9% on lip/buccal mucosa, 9.09%
on palate and 9.09% on mandibule. 59.09% patients
were graded as grade I, 31.81% grade II and 9.09%
grade III. To compare the serum lipid proﬁle between the OSCC patients and controls, the mean
and P-values of all the serum lipid proﬁle values
were calculated and compared. A Signiﬁcant
decrease in serum cholesterol (P ¼ 0.000002), triglyceride (P ¼ 0.038), HDL-C (P ¼ 6.65E-10), LDL-C
(P ¼ 0.011) and VLDL (P ¼ 0.038) concentrations
was found in OSCC patients compared to the
healthy individuals (Fig. 1) which conﬁrmed previous reports by [4,25]. Next, we compared the
values of all the lipid proﬁle with the clinical and
pathological features of patients including tumour
subsite, tumour grade and stage (Tables 2e4). To
this end, OSCC patients were divided in three
groups of well differentiated (grade I), moderately
differentiated (grade II) and poorly differentiated
(grade III). A signiﬁcant cholesterol reduction was
observed between grade I group and healthy individuals (P ¼ 0.0001), also a signiﬁcant lower value
of HDL-C was observed between healthy individuals, grade I (P ¼ 4.9E-8), grade II
(P ¼ 0.00005) and grade III (P ¼ 0.039) groups
(Table 2). To understand whether the values of
lipid proﬁle differ with healthy individuals
depending on the site of tumour, we divided patients into different groups based on the tumour
location and compared the serum lipid proﬁle of
these groups with controls, the obtained results are
shown in Table 3, for instance lower triglyceride
levels in OSCC patients compared to control group
was signiﬁcant only in patients with Maxilla
(P ¼ 0.022) and oral cavity mucosa tumours
(P ¼ 0.019) (See Table 3). Subjects with stage II
(P ¼ 0.019), III (P ¼ 0.007) and IV (P ¼ 0.0002) had
lower cholesterol level compared to controls; the
HDL-C was lower in all the stages I (P ¼ 0.008), II
(P ¼ 0.000003), III (P ¼ 0.0001) and IV (P ¼ 0.00001)
compared to the healthy individuals; also LDL-C
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Fig. 1. Comparison of lipid proﬁle levels between OSCC patients and healthy individuals. (A) Cholesterol, (B) Triglyceride, (C) HDL-C, (D) LDL-C,
(E) VLDL. P < 0.05 is signiﬁcant.

Table 2. Comparison of lipid proﬁle and tumour grade between OSCC patients and healthy controls.
Cholesterol
Healthy Controls
164.61 ± 29.11
Tumour histopathology
Grade I
122.54 ± 34.05
Grade II
141.28 ± 25.89
Grade III
136.5 ± 36.06
p value* comparison of lipid
proﬁle of OSCC and healthy controls
Grade I* Healthy controls
0.0001
Grade II* Healthy controls
0.008
Grade III* Healthy controls
0.142

Triglyceride

HDL-C

LDL-C

VLDL

104.08 ± 31.81

47.00 ± 9.50

90.58 ± 24.00

20.81 ± 6.36

79.92 ± 35.05
87.57 ± 26.41
82.00 ± 26.87

23.61 ± 11.70
29.00 ± 9.50
32.50 ± 9.20

77.80 ± 23.67
88.91 ± 19.45
82.18 ± 30.36

15.98 ± 7.01
17.51 ± 5.28
16.40 ± 5.37

0.351
0.152
0.409

4.9E-8
0.00005
0.039

0.057
0.388
0.563

0.351
0.152
0.409

Grade I: Well differentiated carcinoma; Grade II: Moderately differentiated carcinoma; Grade III: Poorly differentiated carcinoma; HDLC: High density lipoprotein-Cholesterol; LDL-C: Low density lipoprotein-Cholesterol; VLDL: Very low density lipoprotein. P < 0.05 is
signiﬁcant.
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Table 3. Comparison of lipid proﬁle and tumour subsites between OSCC patients and healthy controls.

Healthy Controls
Tumour subsites
Oral cavity
Tongue
Mouth ﬂoor
Lip/Buccal mucosa
Maxilla
Mandible
Palate
p value* comparison of lipid proﬁle of
OSCC and healthy controls
Oral cavity * Healthy controls
Tongue * Healthy controls
Mouth ﬂoor * Healthy controls
Lip/Buccal mucosa* Healthy controls
Maxilla* Healthy controls
Mandible* Healthy controls
Palate* Healthy controls

Cholesterol

Triglyceride

HDL-C

LDL-C

VLDL

164.61 ± 29.11

104.08 ± 31.81

47.00 ± 9.50

90.58 ± 24.00

20.81 ± 6.36

±
±
±
±
±
±
±

30.50 ± 0.71
22.2 ± 11.21
25.50 ± 0.71
24.67 ± 6.80
50.00 ± 9.90
23.00 ± 8.50
19.50 ± 9.19

78.99 ± 1.41
68.95 ± 19.98
74.88 ± 1.24
84.53 ± 25.34
85.06 ± 12.76
105.64 ± 19.65
77.71 ± 32.64

8.90 ± 1.27
19.44 ± 7.28
18.60 ± 0.85
17.00 ± 6.07
9.90 ± 0.14
19.9 ± 2.40
12.20 ± 6.22

0.021
0.000028
0.005
4.9E-7
0.991
0.002
0.001

0.430
0.046
0.304
0.413
0.668
0.436
0.409

0.012
0.881
0.754
0.215
0.022
0.996
0.079

125.50
115.20
125.50
131.78
150.50
155.50
114.50

±
±
±
±
±
±
±

0.71
30.62
0.71
34.15
23.33
31.82
50.20

48.50
97.20
95.50
85.00
49.50
99.50
61.00

0.021
0.001
0.005
0.004
0.991
0.002
0.001

0.019
0.881
0.848
0.215
0.022
0.996
0.079

0.71
36.39
0.71
30.37
0.71
12.02
31.11

HDL-C: High density lipoprotein-Cholesterol; LDL-C: Low density lipoprotein-Cholesterol; VLDL: Very low density lipoprotein.
P < 0.05 is signiﬁcant.
Table 4. Comparison of lipid proﬁle and tumour stage between OSCC patients and healthy controls.
Cholesterol
Healthy Controls
164.61
Tumour stage
Stage I
150.33
Stage II
131.80
Stage III
131.67
Stage IV
111.17
p value* comparison of lipid
proﬁle of OSCC and healthy controls
Stage I* Healthy controls
0.327
Stage II* Healthy controls
0.019
Stage III* Healthy controls
0.007
Stage IV* Healthy controls
0.0002

Triglyceride

HDL-C

LDL-C

VLDL

± 29.11

104.08 ± 31.81

47.00 ± 9.50

90.58 ± 24.00

20.81 ± 6.36

±
±
±
±

90.67
82.40
81.33
74.33

34.99
35.94
24.28
33.23

±
±
±
±

0.613
0.267
0.165
0.058

24.21
39.93
25.00
24.83

31.33
19.80
28.67
22.17

±
±
±
±

6.81
5.58
6.25
11.63

0.008
0.000003
0.0001
0.00001

94.63
89.62
81.37
69.54

0.874
0.816
0.284
0.043

±
±
±
±

30.43
23.73
15.63
24.75

18.13
16.48
16.27
14.87

±
±
±
±

4.84
7.98
5.00
4.97

0.613
0.267
0.165
0.058

HDL-C: High density lipoprotein-Cholesterol; LDL-C: Low density lipoprotein-Cholesterol; VLDL: Very low density lipoprotein.
P < 0.05 is signiﬁcant.

was lower only in stage IV compared to controls
(P ¼ 0.043) (See Table 4).
3.2. Decreased ApoC1 serum concentration in
patients with OSCC compared to healthy
individuals
In order to investigate the clinical value of ApoC-1
serum level, ﬁrst we compared the serum level of
ApoC-1 between OSCC patients and controls to see
whether it is altered in OSCC or not. As indicated in
Fig. 2, the results revealed the signiﬁcant decrease in
serum ApoC-1 of OSCC patients as compared to
healthy individuals (P ¼ 0.001).
3.3. The serum ApoC-1 is not predictive of OSCC
staging, grade and tumour size
The observed alteration in ApoC-1 serum level
of OSCC patients motivated us to examine its

correlation with clinical and pathological features
of patients. Neither tumour size (P ¼ 0.67) nor
grade (P ¼ 0.7) were signiﬁcantly correlated with
serum ApoC-1 concentration (Table 5). Interestingly, we found that for patients with vascular invasion, the ApoC-1 level is statistically higher than
for those without vascular invasion (Fig. 3 and
Table 5).

4. Discussion
Lipids play important roles as energy storage,
structural component of cell membranes and
signaling processes [25,26]. Tumour cells need high
level of lipids to fulﬁll the requirements of cell
rapid proliferation and growth, thus exhibit
changes in lipid metabolism pathways. To this end,
tumour cells show increased lipid uptake, endogenous de novo lipogenesis, oxidation of fatty acids
and
cholesterol
accumulation
[27].
Lipid
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Fig. 2. Comparison of ApoC-1 levels between OSCC patients and
healthy individuals. Distributions of ApoC-1 concentrations in OSCC
patients and controls using box-plots. P < 0.05 is signiﬁcant.

metabolism deregulation is one of the cancer hallmarks and has been considered as promising
therapeutic targets [27]. For instance the overexpression of Fatty Acid Synthase (FASN) which is
a key lipogenic enzyme has been reported to be
associated with proliferation, chemoresistance and
poor prognosis of ovarian cancer and FASN inhibitors have been shown to promote cancer cell
apoptosis [28]. Therefore, the decrease in blood
lipids in some cancers can be due to the effects of
cancer cells' metabolism, disruption of the metabolic pathways of lipids, increased lipid peroxidation and antioxidant vitamins. To compensate for
their lipid deﬁciency, cancer cells increase the
lipogenesis or meet the need for the breakdown of
blood lipoproteins such as HDL-C, LDL-C and
VLDL [7]. Lipoproteins are in charge of delivering
endogenous and exogenous lipids to the tissues
[29]. ApoC-1 as a surface component of lipoproteins including chylomicron, HDL and LDL is
mainly expressed in liver and its oncogenic role has
been reported in pancreatic, breast and lung cancer
[18,30,31]. Several studies declared that ApoC-1
mediates cell survival and the knockdown of
ApoC-1 signiﬁcantly has decreased proliferation of

Fig. 3. Comparison of ApoC-1 levels between OSCC patients with and
without vascular invasion. Box plot showing the distribution of ApoC-1
concentrations in two groups of OSCC patients deﬁned as Yes ¼ with
vascular invasion, No ¼ without vascular invasion. . P < 0.05 is
signiﬁcant.

pancreatic cancer cells and induced apoptosis [18].
This study aimed at investigating both the serum
lipid proﬁle and ApoC-1 levels in OSCC patients
and healthy individuals. We conﬁrm the ﬁndings of
previous studies on lower serum lipid proﬁle
values including TG, cholesterol, HDL-C, LDL-C
and VLDL of OSCC patients compared to the
controls [4,25]. Except to HDL-C, we found a progressive decline in all lipid proﬁle values as stage
increases. Additionally, the serum mean value of
cholesterol compared to healthy individuals is signiﬁcant only for stage III and stage IV. Regarding
the histopathological grades, among all measured
lipids only cholesterol decreases as grade increases.
This is the ﬁrst report that provide evidence on the
signiﬁcant differences of serum ApoC-1 between
OSCC and healthy individuals. We found the lower
serum ApoC-1 level in OSCC compared to the
healthy individuals whereas Song et al. recently
found that the serum level of ApoC-1 was

Table 5. Correlation of ApoC1 with clinicopathological features of OSCC patients.
Sample Size

Groups

ApoC1

Tumour Stage

20

ANOVA pval ¼ 0.989

Tumour Grade
Tumour Size
Tumour Subsites

22
20
22

Stage I (n ¼ 3), Stage II (n ¼ 5),
Stage III (n ¼ 6), Stage IV (n ¼ 6)
e
e
Oral cavity (n ¼ 2), Tongue (n ¼ 5),
Mouth ﬂoor (n ¼ 2), Lip/Buccal mucosa
(n ¼ 9), Maxilla (n ¼ 2), Mandible (n ¼ 2)

Pearson's corr. coef. ¼ 0.08, pval ¼ 0.7
Pearson's corr. coef. ¼ 0.095, pval ¼ 0.673
ANOVA pval ¼ 0.13
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increased in patients with TNBC compared to nonTNBC [30]. On the other hand, Li and colleagues
reported reduction of serum ApoC-1 level of
pancreatic cancer patients after surgery compared
to the preoperative serum conﬁrming that pancreatic cancer cells secrete ApoC-1 [18]. To unravel the
reason behind lower serum level of ApoC-1 in
OSCC patients compared to the healthy individuals, one need to investigate and compare the
ApoC-1 tumour expression with normal oral mucosa tissue. The OSCC patients with vascular invasion showed signiﬁcantly higher ApoC-1 level as
compared to those without invasion. Neither grade
nor stage was associated with signiﬁcant decrease
of serum ApoC-1 level. Taking into account the
location of studied malignancy, saliva ApoC-1 is
more relevant than serum and the recent work by
Hirtz et al. on saliva revealed that ApoC-1 uprepresented in OSCC without lymph node metastasis vs. OSCC_FREE and OSCC with lymph node
metastasis [32]. A future study to measure ApoC-1
on saliva, serum and tissue of the same OSCC
patients and comparing it with healthy individuals
is needed.

5. Conclusion
Decreased lipid proﬁle and ApoC-1 levels in our
study may indicate a correlation between these
factors and the progression of OSCC. The main
limitation of this study was the evaluation of ApoC1 in the serum and tumour tissue of the same patients which could potentially enable us to hypothesize whether OSCC tissue expresses and
secretes ApoC-1 in the serum or not. Additionally,
since the apolipoprotein E (ApoE) and ApoC-1
genes belong to the same gene cluster, it would be
very informative to correlate the decrease in
plasma cholesterol with apoE in future
research. Further investigation to unravel its
prognostic importance is needed and would
potentially lead to a new therapeutic target for
OSCC patients.
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